ScreenerHero

CRBP Corbus Pharmaceuticals Holdings, Inc.

NAS · US · Healthcare · Biotechnology · corbuspharma.com
5.380USD-2.00%Mkt Cap: 106.18M $P/E: —

Corbus Pharmaceuticals Holdings, Inc., a clinical stage company, develops and commercializes therapeutics for cancer and obesity. Its pipeline includes CRB-701, an antibody drug conjugate that targets the expression of N…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$128.08BUSDP/E 29.4
MRNA
Moderna, Inc.
$78.44BUSD
REGN
Regeneron Pharmaceuticals, Inc.
$76.40BUSDP/E 18.4
ARGX
argenx SE
$57.03BUSDP/E 37.3
ARGX
argenx SE
$58.08BUSDP/E 35.4
UCB
UCB SA
$42.24BUSDP/E 18.0
RVMD
Revolution Medicines, Inc.
$43.05BUSD
ONC
BeOne Medicines AG
$41.41BUSDP/E 65.1
RPRX
Royalty Pharma plc
$32.80BUSDP/E 30.2
ALNY
Alnylam Pharmaceuticals, Inc.
$30.03BUSDP/E 37.8
ROIV
Roivant Sciences Ltd.
$25.10BUSD
BNTX
BioNTech SE
$23.93BUSD
INCY
Incyte Corporation
$22.99BUSDP/E 14.5
GMAB
Genmab A/S
$22.27BUSDP/E 30.7
GMAB
Genmab A/S
$22.54BUSDP/E 28.9
INSM
Insmed Incorporated
$22.22BUSD
ASND
Ascendis Pharma A/S
$15.03BUSDP/E 17.5
JAZZ
Jazz Pharmaceuticals plc
$15.01BUSDP/E 15.8
EXEL
Exelixis, Inc.
$14.48BUSDP/E 18.4
SMMT
Summit Therapeutics Inc.
$14.32BUSD

Key Statistics

Company
Market Cap106.18M USD
Enterprise Value-1.88M USD
Revenue (TTM)—
Gross Profit-90.26M USD
Net Income (TTM)-78.54M USD
Revenue/Share—
Last Price5.380 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees36
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-1.05
PEG—
EV/EBITDA0.02
EV/Revenue—
P/S—
P/B1.06
EPS (TTM)-6.02
EPS (Forward)-5.51
52W Range
5.4700% of range20.56
52W High20.56 USD
52W Low5.470 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-53.24%
ROA-46.69%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-64.49M USD
CapEx (TTM)7.00K USD
FCF Margin—
FCF Yield-46.73%
Net Debt-113.68M USD
Net Debt/EBITDA1.07
Balance Sheet
Debt/Equity0.01
Current Ratio5.71
Quick Ratio5.56
Book Value/Sh5.48 USD
Cash/Share6.10 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio—
Ex-Div Date—
Pay Date—
Splits
Last Split1:30
Split DateFeb 14, 2023
Analyst Consensus
Rating1.0 (Strong Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)34.02 USD
Upside (mean)+532.4%
Target Range17.25 USD – 48.00 USD
17.25+532.4% to mean48.00
# Analysts10
Ownership
Shares Out.19.34M
Float13.25M
Insiders1.24%
Institutions84.15%
Short Interest
Short Ratio2.2d
Short % Float16.33%
Short % Out.14.27%
Shares Short2.76M
Short (prev mo.)2.15M
Technical
SMA 509.070 (-40.7%)
SMA 2008.959 (-39.9%)
Beta2.63
S&P 52W Chg16.45%
Avg Vol (30d)1.03M
Avg Vol (10d)736.13K
Technical Indicators
RSI (14)24.1
MACD-0.9809
MACD Signal-0.8187
MACD Hist.-0.1622
BB Upper9.695 USD
BB Middle7.306 USD
BB Lower4.916 USD
BB Width65.43%
ATR (14)0.5412 USD
Vol Ratio (20d)1.06x